What Sicorten plus treats: Main Uses and Benefits

Sicorten plus is generally used in situations involving certain distressing symptoms associated with inflammatory skin conditions. The dual formulation is applied across domains where additional symptomatic support is needed, combining anti-inflammatory and antimicrobial properties.

---

Management of Inflammatory Conditions with Microbial Presence

The medication is commonly used across conditions characterized by periods of heightened symptoms, such as various forms of eczema and dermatitis (e.g., atopic, contact, seborrhoeic), particularly when they are complicated by microbial involvement. This therapeutic area is relevant in contexts that involve symptoms linked to both inflammation and microbial presence. The combination is considered relevant for managing these symptoms, including in presentations such as chronic hand eczema.

This focus ensures comprehensive care during difficult symptomatic phases. “It is commonly used when an inflammatory skin condition presents with a concern for secondary microbial complication.”

---

Supportive Relief from Intense Redness, Swelling, and Itchiness

Sicorten plus is applied in clinical settings that involve acute or unstable symptom patterns. The formulation is used to address pronounced symptoms that become more disruptive during flare-ups, including intense itchiness (pruritus), noticeable redness, and related swelling or exudation during acute episodes. Used during phases of increased distress, the medication supports patients during difficult episodes and may help patients cope more steadily with symptom fluctuations. It contributes to improved comfort when symptoms interfere with routine activities.

The primary conditions the medication is commonly used to help with include atopic dermatitis, contact dermatitis, seborrhoeic dermatitis, and specific presentations of eczema where microbial involvement is a factor.

Quick Fact: Relief for Heightened Symptoms
Primary Symptom Domains	Intense Inflammation, Severe Itchiness, Microbial Involvement
Core Benefit	Supports patients during episodes of heightened discomfort by addressing the symptomatic burden.

Regulatory References

1. ClinicalTrials.gov study overview

Who Can and Cannot Use Sicorten plus?

Eligibility for Sicorten plus (Halometasone/Triclosan Cream) is strictly defined by regulatory authorities based on population safety and the potential for systemic absorption of the potent corticosteroid component. The medicine is generally permitted for adults and children 12 years of age and older for approved indications. However, use is not recommended in children younger than 12 years of age because safety and efficacy are not established and they face a greater risk of systemic side effects.

---

Contraindicated Populations and Conditions

Use is contraindicated in several specific populations and conditions as stated in the official label:

• Patients with known Hypersensitivity to the active ingredients or excipients.
• Patients with Rosacea or Perioral Dermatitis (rash around the mouth).
• Patients with primary skin infections (e.g., viral, fungal) that are not secondary complications of the treated dermatosis.

Restricted Use and Limitations

Application is restricted from the Face, Underarms, and Groin area. Use in pregnancy is conditional and permitted only if the potential benefit justifies the potential risk to the fetus. For lactating patients, application to the nipple or areola is prohibited. Conditional caution is also required for patients with systemic conditions like Diabetes or Cushing's syndrome.

Interactions with other medicines and products

Regulatory documentation defines the interaction profile of Sicorten plus primarily through the Halometasone component, a potent topical corticosteroid with potential for systemic absorption. The official profile reflects established pharmacokinetic and pharmacodynamic interactions for this class of medicine.

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Regulatory Statement
Pharmacokinetic	Strong CYP3A Inhibitors (e.g., Ritonavir, Cobicistat)	Co-administration is documented to inhibit the metabolism of the corticosteroid component.
Exposure Altering	Strong CYP3A Inhibitors	This metabolic inhibition leads to an officially noted increase in the systemic exposure of Halometasone.
Pharmacodynamic	Antidiabetic Agents	Increased systemic exposure carries a risk of counteracting the effects of these medicines.
Pharmacodynamic	Other Glucocorticoids	Concomitant use with other corticosteroid-containing products may result in additive systemic corticosteroid effects.

Official regulatory sources note that the relevance of these interactions is tied directly to the potential for systemic absorption of the potent Halometasone component. No mandatory timing separation rules for co-administration with other medicines are explicitly documented in the regulatory label for this topical preparation.

Fluocinolone acetonide, the corticosteroid component, acts by readily crossing the cell membrane to bind with high affinity to intracellular glucocorticoid receptors (GRs). This binding induces a conformational change, allowing the activated receptor complex to translocate into the nucleus.

Once in the nucleus, the complex binds to specific DNA sequences known as glucocorticoid response elements (GREs), which modulate gene transcription. This process suppresses the expression of numerous pro-inflammatory proteins (e.g., cytokines, chemokines) while increasing the expression of anti-inflammatory proteins, such as lipocortin. Lipocortin then inhibits the enzyme phospholipase A₂ (PLA₂), thereby reducing the formation of arachidonic acid and its downstream inflammatory mediators like prostaglandins and leukotrienes.

Clioquinol, the antimicrobial component, exerts its effect through the chelation of essential metal ions (e.g., iron, copper) required as cofactors for microbial enzyme systems. This interruption of metal-dependent enzymatic processes, particularly in pathogen respiration and nucleic acid synthesis, effectively inhibits the proliferation of susceptible organisms.

How Sicorten plus Is Used

Sicorten plus (Halometasone/Triclosan cream) is used according to standardized administration guidelines, which define the procedure for its application and duration of use. The preparation is designated strictly for topical administration, meaning it is applied directly to the skin surface.

---

Administration and Dosing Protocols

The established protocol outlines the required dosage and frequency for the combination cream. The preparation is applied as a thin film covering the affected area of skin, and this application is typically repeated once or twice daily. It is essential that the cream is rubbed in gently upon application. As an external dermatological preparation, Sicorten plus is not intended for use near the eyes or any other route of administration.

---

Constraints on Treatment Course

There are constraints on how the medicine can be used over time and under specific conditions. Continuous treatment with potent topical corticosteroids, such as the Halometasone component in Sicorten plus, is generally limited to a maximum of 2 consecutive weeks to mitigate risks associated with prolonged use.

A critical administration constraint is the restriction on covering the treated area. The skin area where the cream is applied must not be bandaged or wrapped so as to create an occlusive dressing, unless specific medical direction is provided. This instruction governs the context of application for the combination product. Use in pediatric patients requires careful adherence to prescribing limits regarding both the duration of the course and the percentage of the body surface area treated.

Research evidence / Overview of Studies for Sicorten Plus

1. Evidence for Infected Acute Eczematous Dermatoses

This section will summarize the structure of the primary clinical research, focusing on the comparative clinical trials that evaluated the combination cream for various forms of acute eczema and dermatitis where microbial presence was a factor. The overview will describe which outcomes, such as changes in severity scales and microbial status, were measured in the short-term studies.

Research has primarily focused on conditions associated with acute or disruptive episodes, such as eczema or dermatitis where research examined a microbial presence alongside inflammation. Studies included comparative multicentre trials and other clinical trials involving both adults and children. These research scenarios explored short-term symptom changes, with observation periods typically lasting only two to three weeks.

Findings describe patterns observed in the studies, where researchers tracked changes in investigator-assessed severity scales and observed microbial presence in the study populations. The evidence contributes to understanding symptom patterns measured during the brief study period. However, the current follow-up durations were limited. Long-term effects are not fully established.

2. Research on Chronic Skin Conditions

This section outlines the available data regarding the use of the cream in chronic inflammatory skin issues, such as keratinized hand eczema. The summary will detail the types of non-comparative and exploratory studies that exist and what functional and quality-of-life outcomes were assessed in these particular patient groups.

The combination was studied in research exploring chronic keratinized hand eczema in adults, a condition marked by functional limitations. These were often non-comparative open-label studies applied in research contexts involving fluctuating or unstable symptoms. The data describes patterns related to measurements from specific assessment tools, such as the Hand Eczema Severity Index (HECSI). Findings describe group patterns, and research does not determine whether an individual will respond similarly.

3. Long-Term Outcomes and Follow-up Duration

Research examined short-term symptom changes, primarily in the acute eczema studies, focusing on immediate observations (10 to 21 days). Consequently, follow-up durations were limited. This means that long-term effects are not fully established regarding symptom stability or how the conditions may evolve over months or years. Data for sustained responses are insufficient, and the research contributes to the broader evidence landscape but provides limited context for long-term use.

Key Studies & References

1. Swissmedic Compendium: Official Professional Information for Medicinal Products
2. Effectiveness and Safety of Halometasone/Triclosan Cream in Chronic Hand Eczema (NCT03246776)

Common questions about Sicorten plus (FAQ)

Q: What is Sicorten plus used to treat?

Official product information states that Sicorten plus is indicated for the management of inflammatory skin conditions, such as certain types of eczema or dermatitis. This combination cream is generally reserved for use when these inflammatory conditions are complicated by, or are suspected of being complicated by, infection with susceptible microorganisms. The formulation is designed to address both inflammation and potential microbial presence simultaneously.

Q: How does Sicorten plus work to reduce inflammation?

The cream works through a dual action mechanism, combining the effects of two active ingredients. The Halometasone component is a potent corticosteroid that helps mitigate the symptoms of inflammation, such as redness and swelling. The Triclosan component functions as an antimicrobial agent to help control and limit the growth of microorganisms on the skin's surface.

Q: What should I do if I forget a dose of Sicorten plus?

Official labeling advises applying the cream as soon as it is remembered if a dose is missed. However, if it is almost time for the next dose, it is generally advised to skip the missed dose and resume the regular treatment schedule. Regulatory information emphasizes that extra cream or a double quantity should not be applied to compensate for a missed dose.

Q: What are the most common side effects of Sicorten plus?

According to official regulatory sources, the most commonly reported side effects occur at the area where the cream is applied. These may include temporary local effects such as irritation, a burning sensation, itching, or rash. Temporary discoloration of the skin, hair, or contact materials like clothing may be observed, which is associated with the antimicrobial component.

Q: What is the difference between Sicorten plus and regular Sicorten?

Sicorten plus is a combination product because it contains two active ingredients: the corticosteroid Halometasone and the antimicrobial Triclosan. Regulatory information indicates that the product referred to as 'regular' Sicorten (without the 'plus') contains only the corticosteroid component, Halometasone. The addition of the antimicrobial is what distinguishes the 'plus' formulation.

Q: What ingredients are in the cream base (excipients)?

The cream contains the active ingredients Halometasone and Triclosan, which are carried in a cream base made up of inactive ingredients (known as excipients). These excipients include substances like water, oils, and stabilizers to give the product its texture and help its application. A complete list of these inactive ingredients is provided in the official prescribing information for the product.

Q: Can I use Sicorten plus with makeup or moisturizers?

Official product warnings focus on application methods, specifically cautioning against applying the cream under any type of occlusive dressing or covering. This instruction highlights the risk that covering the area may increase the systemic absorption of the active ingredients. The restriction governs what you can safely cover the treated skin with.

How to Store and Dispose of Sicorten plus?

The storage and disposal of Sicorten plus cream must follow regulatory requirements to maintain the product's stability and ensure safety.

Storage Requirements

Item	Requirement
Temperature	Store below 25°C (77°F).
Protection	Keep the cream from freezing and protect it from direct light and moisture.
Container	Store in the original container and keep the tube tightly closed.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused cream should be handled as pharmaceutical waste. Do not dispose of the cream via the wastewater system (flushing). The product must be disposed of according to national and local regulations for pharmaceutical waste, ideally by returning it to an authorized drug take-back program.